1. P-209P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. (20th June 2018) Authors: Puzzoni, M; Demurtas, L; Ziranu, P; Lai, E; Giampieri, R; Faloppi, L; Mandolesi, A; Cremolini, C; Masi, G; Gelsomino, F; Mariani, S; Cubeddu, A; Casula, L; Liscia, N; Pusceddu, V; Antoniotti, C; Loretelli, C; Meriggi, F; Zaniboni, A; Falcone, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-209P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. (20th June 2018) Authors: Puzzoni, M; Demurtas, L; Ziranu, P; Lai, E; Giampieri, R; Faloppi, L; Mandolesi, A; Cremolini, C; Masi, G; Gelsomino, F; Mariani, S; Cubeddu, A; Casula, L; Liscia, N; Pusceddu, V; Antoniotti, C; Loretelli, C; Meriggi, F; Zaniboni, A; Falcone, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗